Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia
- PMID: 25277610
- DOI: 10.1016/j.jacc.2014.01.088
Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia
Abstract
Background: Patients with familial hypercholesterolemia (FH) are characterized by elevated atherogenic lipoprotein particles, predominantly low-density lipoprotein cholesterol (LDL-C), which is associated with accelerated atherogenesis and increased cardiovascular risk.
Objectives: This study used (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) to investigate whether arterial inflammation is higher in patients with FH and, moreover, whether lipoprotein apheresis attenuates arterial wall inflammation in FH patients.
Methods: In total, 38 subjects were recruited: 24 FH patients and 14 normolipidemic controls. All subjects underwent FDG-PET imaging at baseline. Twelve FH patients who met the criteria for lipoprotein apheresis underwent apheresis procedures followed by a second FDG-PET imaging 3 days (range 1 to 4 days) after apheresis. Subsequently, the target-to-background ratio (TBR) of FDG uptake within the arterial wall was assessed.
Results: In FH patients, the mean arterial TBR was higher compared with healthy controls (2.12 ± 0.27 vs. 1.92 ± 0.19; p = 0.03). A significant correlation was observed between baseline arterial TBR and LDL-C (R = 0.37; p = 0.03) that remained significant after adjusting for statin use (β = 0.001; p = 0.02) and atherosclerosis risk factors (β = 0.001; p = 0.03). LDL-C levels were significantly reduced after lipoprotein apheresis (284 ± 118 mg/dl vs. 127 ± 50 mg/dl; p < 0.001). There was a significant reduction of arterial inflammation after lipoprotein apheresis (TBR: 2.05 ± 0.31 vs. 1.91 ± 0.33; p < 0.02).
Conclusions: The arterial wall of FH patients is characterized by increased inflammation, which is markedly reduced after lipoprotein apheresis. This lends support to a causal role of apoprotein B-containing lipoproteins in arterial wall inflammation and supports the concept that lipoprotein-lowering therapies may impart anti-inflammatory effects by reducing atherogenic lipoproteins.
Keywords: PET/CT imaging; atherosclerosis.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Lipoprotein apheresis and acute reduction of arterial inflammation: FDG-PET as an imaging biomarker of nonpharmacological effects on the vessel wall.J Am Coll Cardiol. 2014 Oct 7;64(14):1427-9. doi: 10.1016/j.jacc.2014.06.1197. J Am Coll Cardiol. 2014. PMID: 25277611 No abstract available.
Similar articles
-
Lipoprotein apheresis.Cardiol Clin. 2015 May;33(2):197-208. doi: 10.1016/j.ccl.2015.02.002. Cardiol Clin. 2015. PMID: 25939293 Review.
-
A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography.Acad Radiol. 2015 May;22(5):600-9. doi: 10.1016/j.acra.2014.12.015. Epub 2015 Feb 21. Acad Radiol. 2015. PMID: 25708866 Clinical Trial.
-
Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.J Clin Lipidol. 2016 Jan-Feb;10(1):124-33. doi: 10.1016/j.jacl.2015.10.006. Epub 2015 Oct 17. J Clin Lipidol. 2016. PMID: 26892129
-
Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S21-6. doi: 10.1016/j.jacl.2013.03.002. Epub 2013 Mar 26. J Clin Lipidol. 2013. PMID: 23642325
-
Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.Am J Cardiovasc Drugs. 2011 Dec 1;11(6):363-70. doi: 10.2165/11594970-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 22149315 Review.
Cited by
-
Fabrication and Study of Dextran/Sulfonated Polysulfone Blend Membranes for Low-Density Lipoprotein Adsorption.Materials (Basel). 2023 Jun 27;16(13):4641. doi: 10.3390/ma16134641. Materials (Basel). 2023. PMID: 37444954 Free PMC article.
-
Imaging systemic inflammatory networks in ischemic heart disease.J Am Coll Cardiol. 2015 Apr 21;65(15):1583-91. doi: 10.1016/j.jacc.2015.02.034. J Am Coll Cardiol. 2015. PMID: 25881940 Free PMC article. Review.
-
Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies.J Clin Med. 2019 Jan 18;8(1):118. doi: 10.3390/jcm8010118. J Clin Med. 2019. PMID: 30669380 Free PMC article. Review.
-
Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study.J Atheroscler Thromb. 2024 Oct 1;31(10):1370-1385. doi: 10.5551/jat.64639. Epub 2024 Apr 3. J Atheroscler Thromb. 2024. PMID: 38569869 Free PMC article.
-
Imaging inflammation and neovascularization in atherosclerosis: clinical and translational molecular and structural imaging targets.Curr Opin Cardiol. 2015 Nov;30(6):671-80. doi: 10.1097/HCO.0000000000000226. Curr Opin Cardiol. 2015. PMID: 26398413 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
